These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20880295)

  • 1. Pathophysiology of multiple sclerosis and the place of teriflunomide.
    Gold R; Wolinsky JS
    Acta Neurol Scand; 2011 Aug; 124(2):75-84. PubMed ID: 20880295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune mechanisms of new therapeutic strategies in MS: teriflunomide.
    Claussen MC; Korn T
    Clin Immunol; 2012 Jan; 142(1):49-56. PubMed ID: 21367665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
    O'Connor P; Wolinsky JS; Confavreux C; Comi G; Kappos L; Olsson TP; Benzerdjeb H; Truffinet P; Wang L; Miller A; Freedman MS;
    N Engl J Med; 2011 Oct; 365(14):1293-303. PubMed ID: 21991951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
    Brunetti L; Wagner ML; Maroney M; Ryan M
    Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriflunomide for the treatment of multiple sclerosis.
    Warnke C; Stüve O; Kieseier BC
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teriflunomide encourages cytostatic and apoptotic effects in premalignant and malignant cutaneous keratinocytes.
    Hail N; Chen P; Rower J; Bushman LR
    Apoptosis; 2010 Oct; 15(10):1234-46. PubMed ID: 20544286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teriflunomide for oral therapy in multiple sclerosis.
    Papadopoulou A; Kappos L; Sprenger T
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):617-28. PubMed ID: 23234322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on teriflunomide.
    Tallantyre E; Evangelou N; Constantinescu CS
    Int MS J; 2008 Jun; 15(2):62-8. PubMed ID: 18782502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide and its mechanism of action in multiple sclerosis.
    Bar-Or A; Pachner A; Menguy-Vacheron F; Kaplan J; Wiendl H
    Drugs; 2014 Apr; 74(6):659-74. PubMed ID: 24740824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teriflunomide for the treatment of multiple sclerosis.
    Oh J; O'Connor PW
    Semin Neurol; 2013 Feb; 33(1):45-55. PubMed ID: 23709212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.
    Scott LJ
    Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of diagnosis and early treatment on the course of multiple sclerosis.
    Noyes K; Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.
    Bar-Or A
    Exp Neurol; 2014 Dec; 262 Pt A():57-65. PubMed ID: 24925677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS].
    Bencsik K; Rózsa C; Vécsei L
    Ideggyogy Sz; 2015 Mar; 68(3-4):79-87. PubMed ID: 26434194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW; Li D; Freedman MS; Bar-Or A; Rice GP; Confavreux C; Paty DW; Stewart JA; Scheyer R; ;
    Neurology; 2006 Mar; 66(6):894-900. PubMed ID: 16567708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teriflunomide: a review of its use in relapsing multiple sclerosis.
    Garnock-Jones KP
    CNS Drugs; 2013 Dec; 27(12):1103-23. PubMed ID: 24198223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
    Wiese MD; Rowland A; Polasek TM; Sorich MJ; O'Doherty C
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1025-35. PubMed ID: 23682862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.